|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date16 Nov 2015 |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Janssen R&D Ireland Share Participation Scheme
0 Patents (Medical) associated with Janssen R&D Ireland Share Participation Scheme
100 Deals associated with Janssen R&D Ireland Share Participation Scheme
100 Translational Medicine associated with Janssen R&D Ireland Share Participation Scheme